Wall Street analysts expect AtriCure Inc. (NASDAQ:ATRC) to post $51.62 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for AtriCure’s earnings. The highest sales estimate is $52.90 million and the lowest is $50.76 million. AtriCure reported sales of $46.06 million during the same quarter last year, which indicates a positive year over year growth rate of 12.1%. The company is scheduled to announce its next quarterly earnings results after the market closes on Thursday, February 28th.
On average, analysts expect that AtriCure will report full year sales of $200.37 million for the current financial year, with estimates ranging from $199.50 million to $201.70 million. For the next fiscal year, analysts forecast that the company will post sales of $223.93 million, with estimates ranging from $221.98 million to $225.10 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that cover AtriCure.
ATRC has been the subject of several recent analyst reports. Needham & Company LLC reissued a “buy” rating and set a $39.00 price objective on shares of AtriCure in a report on Friday, October 12th. Zacks Investment Research lowered AtriCure from a “buy” rating to a “hold” rating in a research note on Tuesday, October 23rd. Finally, BidaskClub lowered AtriCure from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, November 13th. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $35.60.
A number of institutional investors and hedge funds have recently modified their holdings of ATRC. AMS Capital Ltda bought a new stake in AtriCure in the third quarter valued at approximately $725,000. Federated Investors Inc. PA bought a new stake in AtriCure in the third quarter valued at approximately $34,000. Ibex Investors LLC bought a new stake in AtriCure in the third quarter valued at approximately $204,000. FMR LLC lifted its position in AtriCure by 1.4% in the second quarter. FMR LLC now owns 5,255,607 shares of the medical device company’s stock valued at $142,164,000 after purchasing an additional 71,961 shares during the last quarter. Finally, GSA Capital Partners LLP lifted its position in AtriCure by 78.2% in the third quarter. GSA Capital Partners LLP now owns 46,424 shares of the medical device company’s stock valued at $1,626,000 after purchasing an additional 20,370 shares during the last quarter. 81.50% of the stock is owned by institutional investors and hedge funds.
Shares of NASDAQ ATRC traded up $0.34 during midday trading on Monday, hitting $31.31. 131,928 shares of the company’s stock were exchanged, compared to its average volume of 158,046. AtriCure has a 12-month low of $14.88 and a 12-month high of $36.49. The company has a current ratio of 2.62, a quick ratio of 1.96 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $1.21 billion, a price-to-earnings ratio of -37.72 and a beta of 0.27.
AtriCure Company Profile
AtriCure, Inc provides atrial fibrillation solutions to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery.
Recommended Story: What Are Treasury Bonds?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.